DDInter1259 DDInter607
Nalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase.
Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular events. It is the first T2DM drug approved to reduce major adverse cardiovascular events (MACE) risk in primary and secondary prevention populations.
Nalidixic acid {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dulaglutide
Nalidixic acid {u} (Compound) resembles {v} (Compound) Norfloxacin
Norfloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dulaglutide
Nalidixic acid {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sitagliptin
Sitagliptin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dulaglutide
Nalidixic acid {u} (Compound) resembles {v} (Compound) Norfloxacin
Norfloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sitagliptin
Sitagliptin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dulaglutide
Nalidixic acid {u} (Compound) resembles {v} (Compound) Rosoxacin
Rosoxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dulaglutide
Nalidixic acid {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} may lead to a major life threatening interaction when taken with {v} Fludrocortisone
Fludrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dulaglutide
Nalidixic acid {u} (Compound) resembles {v} (Compound) Norfloxacin
Norfloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clarithromycin
Clarithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dulaglutide
Nalidixic acid {u} (Compound) resembles {v} (Compound) Lomefloxacin
Lomefloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clarithromycin
Clarithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dulaglutide
Nalidixic acid {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Trovafloxacin
Trovafloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dulaglutide
Nalidixic acid {u} (Compound) resembles {v} (Compound) Norfloxacin
Norfloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dulaglutide
Nalidixic acid (Compound) resembles Enoxacin (Compound) and Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Nalidixic acid (Compound) resembles Norfloxacin (Compound) and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Nalidixic acid (Compound) resembles Enoxacin (Compound) and Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Nalidixic acid (Compound) resembles Norfloxacin (Compound) and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Nalidixic acid (Compound) resembles Rosoxacin (Compound) and Rosoxacin (Compound) resembles Enoxacin (Compound) and Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Nalidixic acid (Compound) resembles Enoxacin (Compound) and Enoxacin may lead to a major life threatening interaction when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Nalidixic acid (Compound) resembles Norfloxacin (Compound) and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Nalidixic acid (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Nalidixic acid (Compound) resembles Enoxacin (Compound) and Enoxacin (Compound) resembles Trovafloxacin (Compound) and Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Nalidixic acid (Compound) resembles Norfloxacin (Compound) and Norfloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide